| 2025-12-03 |
CMDUEID0906022 |
BAXTER HEALTHCARE CORP |
15617.0 kg |
271019.0
|
CARGO IS STOWED IN A REFRIGERATED CONTAINER STHE SHIPPER S REQUESTED CARRYING TEMPERATURE DEGREES CELSIUS X HR CORRUGATED BOXES (PACKED IN WOODEN PALLETS) ONDANSETRON INJECTION USP MG / ML GV ML - , HTS NO.: . . FUROSEMIDE INJECTION USP MG/ML ML GV - , HTS NO.: . . INVOICE NO.: S/BILL NO.: DTD: -OCT- TOTAL NET WT.: . KGS TOTAL GROSS WT.: . KGS TEMPERATURE MAINTAIN: PLUS . DEG.C TO DEG.C. TEMPERATURE SETTING: PLUS DEG.C. PLACE OF DELIVERY: BYHALIA, MS FREIGHT COLLECT, |
| 2025-09-16 |
EXDO6630056141 |
BAXTER HEALTHCARE CORP |
8683.0 kg |
291813.0
|
METOPROLOL TARTRATE INJECTION HTS: |
| 2025-06-03 |
EXDO6630054401 |
BAXTER HEALTHCARE CORP |
7515.0 kg |
300490
|
METOPROLOL TARTRATE INJECTION HTS: 30049074 |
| 2025-03-12 |
EXDO6630053264 |
BAXTER HEALTHCARE CORP |
5619.0 kg |
300490
|
PHARMA PRODUCTS HTS: 300490 |
| 2025-02-21 |
CMDUEID0843873 |
BAXTER HEALTHCARE CORP |
13165.0 kg |
300490
|
CARGO IS STOWED IN A REFRIGERATED CONTAINER STHE SHIPPER S REQUESTED CARRYING TEMPERATURE DEGREES CELSIUS SI REF :24300783 300490 (HS) FWDR REF: 5630017730 CNEE REF: 231-78902091613 CNEE REF: FCA PHARMA PRODUCTS 1499 CORRUGATED BOXES (PACKED IN 14 WOODEN PALLETS) ONDANSETRON INJECTION USP 2MG / ML GV 2ML - 217,800 HTS NO.: 3004.90.9260 FUROSEMIDE INJECTION USP 10MG/ML 4 ML GV - 456,750 HTS NO.: 3004.90.9265 INV. NO.: 24300783 DTD: 31-DEC-2024 S/BILL NO.: 6938958 DTD: 01-JAN-2025 TOTAL NET WT.: 7126.000 KGS TOTAL GROSS WT.: 8505.000 KGS TEMPERATURE SETTING: PLUS 18 DEG.C. PLACE OF DELIVERY: BYHALIA, MS FREIGHT COLLECT, |
| 2025-02-01 |
CMDUEID0840365 |
BAXTER HEALTHCARE CORP |
15280.0 kg |
300490
|
CARGO IS STOWED IN A REFRIGERATED CONTAINER SAT THE SHIPPER S REQUESTED CARRYING TEMPERATUOF 18 DEGREES CELSIUS 300490 (HS) FWDR REF: 5630017589 CNEE REF: FCA PHARMA PRODUCTS 1987 CORRUGATED BOXES (PACKED IN 20 WOODEN PALLETS) FUROSEMIDE INJECTION USP 10MG/ML 2 ML GV - 439,200 HTS NO.: 3004.90.9265 FUROSEMIDE INJECTION USP 10MG/ML 4 ML GV - 454,950 HTS NO.: 3004.90.9265 INV. NO.: 24300741 DTD: 12-DEC-2024 S/BILL NO.: 6393803 DTD: 12-DEC-2024 TOTAL NET WT.: 8078.850 KGS TOTAL GROSS WT.: 10670.000 KGS TEMPERATURE SETTING: PLUS 18 DEG.C. FREIGHT COLLECT |
| 2025-02-01 |
CMDUEID0840367 |
BAXTER HEALTHCARE CORP |
15970.0 kg |
300490
|
CARGO IS STOWED IN A REFRIGERATED CONTAINER SAT THE SHIPPER S REQUESTED CARRYING TEMPERATUOF 18 DEGREES CELSIUS PHARMA PRODUCTS 1808 CORRUGATED BOXES (PACKED IN 20 WOODEN PALLETS) FUROSEMIDE INJECTION USP 10MG/ML 4 ML GV CIVICA - 114,300 HTS NO.: 3004.90.9265 FUROSEMIDE INJECTION USP 10MG/ML 4 ML GV - 572,400 HTS NO.: 3004.90.9265 METOPROLOL TARTRATE INJECTION USP 1MG/ML 5ML GLASS VIAL - 126,900 HTS NO.: 3004.49.0070 INV NO.: 24300744 DTD: 16-DEC-2024 S/BILL NO.: 6476669 DTD: 16-DEC-2024 TOTAL NET WT.: 9162.000 KGS TOTAL GROSS WT.: 11370.000 KGS TEMPERATURE SETTING: PLUS 18 DEG.C. |
| 2025-02-01 |
CMDUEID0842869 |
BAXTER HEALTHCARE CORP |
13596.0 kg |
300449
|
CARGO IS STOWED IN A REFRIGERATED CONTAINER STHE SHIPPER S REQUESTED CARRYING TEMPERATURE DEGREES CELSIUS 300490 (HS) FWDR REF: 5630017685 CNEE REF: FCA PHARMA PRODUCTS 1485 CORRUGATED BOXES (PACKED IN 20 WOODEN PALLETS) METOPROLOL TARTRATE INJECTION USP 1MG/ML 5ML GLASS VIAL - 217,800 HTS NO.: 3004.49.0070 FUROSEMIDE INJECTION USP 10MG/ML 2 ML GV - 220,950 HTS NO.: 3004.90.9265 FUROSEMIDE INJECTION USP 10MG/ML 4 ML GV - 229,500 HTS NO.: 3004.90.9265 S/BILL NO.: 6772213 DTD: 26-DEC-2024 TOTAL NET WT.: 6902.550 KGS TOTAL GROSS WT.: 8996.000 KGS TEMPERATURE SETTING: PLUS 18 DEG.C. FREIGHT COLLECT, FINAL PLACE OF DELIVERY : BYHALIA, MS |
| 2024-10-09 |
EXDO6630050994 |
BAXTER HEALTHCARE CORP |
6092.0 kg |
300490
|
PHARMA HTS: 300490 |
| 2024-10-09 |
EXDO6630050893 |
BAXTER HEALTHCARE CORP |
7963.0 kg |
300490
|
PHARMA HTS: 300490 |
| 2024-02-21 |
EXDO6630048030 |
BAXTER HEALTHCARE CORP |
7990.0 kg |
300490
|
PHARMA HTS: 300490 |
| 2024-02-21 |
EXDO6630048031 |
BAXTER HEALTHCARE CORP |
5460.0 kg |
300490
|
PHARMA HTS: 300490 |
| 2022-12-27 |
EXDO6630041566 |
BAXTER HEALTHCARE CORP |
6472.0 kg |
300490
|
PHARMA HTS: 300490 |
| 2022-12-07 |
EXDO6630041269 |
BAXTER HEALTHCARE CORP |
9287.0 kg |
300490
|
PHARMA HTS: 300490 |
| 2022-11-28 |
EXDO6630041128 |
BAXTER HEALTHCARE CORP |
9431.0 kg |
300490
|
METOPROLOL HTS: 300490 |
| 2022-11-28 |
EXDO6630041131 |
BAXTER HEALTHCARE CORP |
4845.0 kg |
300490
|
PHARMA PRODUCT HTS: 300490 |
| 2022-11-28 |
EXDO6630041129 |
BAXTER HEALTHCARE CORP |
9140.0 kg |
300490
|
PHARMA PRODUCT HTS: 300490 |
| 2022-11-21 |
EXDO6630040943 |
BAXTER HEALTHCARE CORP |
9708.0 kg |
300490
|
PHARMA PRODUCT HTS: 300490 |
| 2022-11-21 |
EXDO6630040944 |
BAXTER HEALTHCARE CORP |
10035.0 kg |
300490
|
PHARMA PRODUCT HTS: 300490 |
| 2022-11-14 |
EXDO6630040832 |
BAXTER HEALTHCARE CORP |
9779.0 kg |
300490
|
ONDANSETRON INJECTION HTS: 300490 |
| 2022-10-31 |
EXDO6630040543 |
BAXTER HEALTHCARE CORP |
9198.0 kg |
300490
|
PHARMA PRODUCT HTS: 300490 |
| 2022-10-31 |
EXDO6630040544 |
BAXTER HEALTHCARE CORP |
10905.0 kg |
300490
|
PHARMA PRODUCT HTS: 300490 |
| 2022-10-21 |
EXDO6630040308 |
BAXTER HEALTHCARE CORP |
7905.0 kg |
300490
|
FUROSEMIDE INJECTION USP HTS: 3004909265 |
| 2022-09-19 |
EXDO6630039868 |
BAXTER HEALTHCARE CORP |
9998.0 kg |
300490
|
PHARMA PRODUCTS HTS: 300490 |
| 2022-09-16 |
EXDO6630039754 |
BAXTER HEALTHCARE CORP |
9430.0 kg |
300490
|
PHARMA PRODUCT HTS: 300490 |
| 2022-09-16 |
EXDO6630039756 |
BAXTER HEALTHCARE CORP |
9430.0 kg |
300420
|
PHARMA PRODUCT HTS: 300420 |
| 2022-09-16 |
EXDO6630039755 |
BAXTER HEALTHCARE CORP |
9444.0 kg |
300420
|
PHARMA PRODUCT HTS: 300420 |
| 2022-09-11 |
EXDO6630039556 |
BAXTER HEALTHCARE CORP |
9444.0 kg |
300420
|
CIPROFLOXACIN IN DEXTROSE HTS: 3004200060 |
| 2022-09-11 |
EXDO6630039557 |
BAXTER HEALTHCARE CORP |
9451.0 kg |
300420
|
CIPROFLOXACIN IN DEXTROSE HTS: 3004200060 |
| 2022-09-11 |
EXDO6630039555 |
BAXTER HEALTHCARE CORP |
9386.0 kg |
300420
|
CIPROFLOXACIN IN DEXTROSE HTS: 300420060 |
| 2022-09-11 |
EXDO6630039610 |
BAXTER HEALTHCARE CORP |
9444.0 kg |
300420
|
CIPROFLOXACIN IN DEXTROSE HTS: 3004200060 |
| 2022-09-03 |
EXDO6630039378 |
BAXTER HEALTHCARE CORP |
9437.0 kg |
300420
|
CIPROFLOXACIN IN DEXTROSE HTS: 3004200060 |
| 2022-09-03 |
EXDO6630039379 |
BAXTER HEALTHCARE CORP |
9437.0 kg |
300490
|
PHARMA PRODUCTS HTS: 300490 |
| 2022-09-03 |
EXDO6630039377 |
BAXTER HEALTHCARE CORP |
9043.0 kg |
300490
|
PHARMA PRODUCTS HTS: 300490 |
| 2022-08-27 |
EXDO6630039267 |
BAXTER HEALTHCARE CORP |
10143.0 kg |
300490
|
PHARMA PRODUCTS HTS: 300490 |
| 2022-08-27 |
EXDO6630039268 |
BAXTER HEALTHCARE CORP |
8500.0 kg |
|
PHARMA PRODUCT |
| 2022-08-12 |
EXDO6630039059 |
BAXTER HEALTHCARE CORP |
8769.0 kg |
300490
|
FLUMAZENIL INJECTION USP HTS: 3004909260 |
| 2022-08-12 |
EXDO6630038873 |
BAXTER HEALTHCARE CORP |
10096.0 kg |
300449
|
METOPROLOL TARTRATE INJECTION USP 1MG HTS: 3004490070 |
| 2022-08-08 |
EXDO6630038872 |
BAXTER HEALTHCARE CORP |
8992.0 kg |
300490
|
PHARMA PRODUCT HTS: 300490 |
| 2022-07-28 |
EXDO6630039984 |
BAXTER HEALTHCARE CORP |
9453.0 kg |
300490
|
PHARMA PRODUCTS HTS: 300490 |
| 2022-07-21 |
EXDO6630040131 |
BAXTER HEALTHCARE CORP |
9240.0 kg |
300490
|
PHARMA PRODUCT HTS: 300490 |
| 2022-07-21 |
EXDO6630040038 |
BAXTER HEALTHCARE CORP |
6449.0 kg |
300490
|
PHARMA PRODUCT HTS: 300490 |
| 2022-07-01 |
EXDO6630038416 |
BAXTER HEALTHCARE |
8804.0 kg |
291813
|
METOPROLOL TARTRATE INJECTION |
| 2022-07-01 |
EXDO6630038415 |
BAXTER HEALTHCARE |
10440.0 kg |
291813
|
METOPROLOL TARTRATE INJECTION |
| 2022-06-22 |
EXDO6630038069 |
BAXTER HEALTHCARE |
9968.0 kg |
|
PHARMA PRODUCTS |
| 2022-06-22 |
EXDO6630038068 |
BAXTER HEALTHCARE |
8711.0 kg |
|
PHARMA PRODUCTS |
| 2022-06-18 |
EXDO6630037907 |
BAXTER HEALTHCARE |
10781.0 kg |
848041
|
FUROSEMIDE INJECTION US |
| 2022-06-18 |
EXDO6630037908 |
BAXTER HEALTHCARE |
10776.0 kg |
848041
|
FUROSEMIDE INJECTION |
| 2022-06-05 |
EXDO6630037796 |
BAXTER HEALTHCARE |
9367.0 kg |
|
CIPROFLOXACIN IN DEXTROSE |
| 2022-06-05 |
EXDO6630037798 |
BAXTER HEALTHCARE |
8185.0 kg |
848041
|
FUROSEMIDE INJECTION |